NASA’s Cloud-Aerosol Lidar and Infrared Pathfinder Satellite Observations (CALIPSO) and CloudSat satellites are set to launch aboard a Boeing Delta II rocket at 3:02 a.m. PDT on Friday, April 21, from ...
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Century Therapeutics, Inc. is conducting ...
– Expansion of Phase 1 CALiPSO-1 trial of CNTY-101 in autoimmune disease to include diffuse cutaneous systemic sclerosis and idiopathic inflammatory myopathy – – Overall response rate (ORR) of 83% ...
Hosted on MSN
Century Therapeutics Reports Positive Q1 2025 Results and Advances in Cell Therapy Pipeline
PHILADELPHIA, PA — Century Therapeutics, Inc. (NASDAQ: IPSC) reported notable progress in Q1 2025, emphasizing advancements in its clinical and preclinical iPSC-derived cell therapy programs.
Piper Sandler lowered the firm’s price target on Century Therapeutics (IPSC) to $4 from $12 and keeps an Overweight rating on the shares. Century is conducting the Phase I CALiPSO-1 study of CNTY-101 ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results